Related Experiment Video
Updated: Feb 7, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Selecting the right biologic for your patients with severe asthma
Laurie A Manka1, Michael E Wechsler1
1Division of Pulmonary, Critical Care, and Sleep Medicine, National Jewish Health, and The NJH Cohen Family Asthma Institute, Denver, Colorado.
Biologic medications targeting type 2 inflammation can improve outcomes for severe asthma patients. Clinicians should consider asthma endotype, biomarkers, and patient factors when selecting the best treatment.
Area of Science:
- Pulmonology and Immunology
- Pharmacology
Background:
- Severe asthma impacts 5-10% of adults, leading to higher morbidity and healthcare costs.
- Biologic therapies targeting the type 2 inflammatory pathway (IL-4, IL-5, IL-13) are emerging treatments.
- Type 2 inflammation is characterized by eosinophilia, elevated FeNO, and atopic features.
Purpose of the Study:
- To provide clinicians with key considerations for selecting appropriate biologic medications for severe asthma.
- To review the efficacy of biologic therapies in managing type 2-high severe asthma.
Main Methods:
- Comprehensive literature search of basic science and clinical trial data.
- Review of studies analyzing biologic medication outcomes in type 2-high severe asthma.
- Analysis of clinical biomarkers, exacerbation rates, lung function, and quality of life.
Main Results:
- Biologic medications significantly improve clinical biomarkers, reduce exacerbation rates, and enhance lung function and quality of life in type 2-high severe asthma.
- These therapies effectively target key mediators of type 2 airway inflammation.
Conclusions:
- Biologic therapies offer significant benefits for patients with severe asthma.
- Selection of biologic medication should be individualized based on asthma endotype, clinical biomarkers, and patient-centered factors.
Related Concept Videos
Asthma-I: Introduction
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
What is Conservation Biology?

